This means: A clear diagnosis must support why IV treatment is required
clinical complexity slows uptake Long-acting or micro-dosages (e.g., monthly injections, microneedle patches) What changes: Improved tolerability, better adherence Where it moves : Possibly back toward DTC models if access outpaces infra Strategic shift: Less patient burden, potential wedge for intermediaries Risk: Manufacturing lag or cost may stall rollout
doi: 10.1371/journal.pone.0148978 67 ParedesJ
DeVore S, Reimer H, Meihofer A, Miner K, Martinez G
The VNAR-C4:sol huTNF- crystallization and X-ray structural determination were carried out at the Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis